[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622990":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":50,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":75,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Ege University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tranexamic Acid Group","EXPERIMENTAL","Participants randomized to this arm will receive a single dose of tranexamic acid (1 g) administered intravenously immediately after fetal delivery during cesarean section, in addition to standard surgical and uterotonic management.",[13],"Drug: Tranexamic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Participants randomized to this arm will receive standard surgical and uterotonic management during cesarean section without the administration of tranexamic acid.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Tranexamic Acid","Tranexamic acid 1 g will be administered intravenously as a single dose immediately after fetal delivery during cesarean section, in addition to standard surgical and uterotonic management.",[9],[26],{"name":27,"affiliation":28,"role":29},"Sabahattin Anıl A ARI, Associate Professor","Izmir Bakircay University","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},"Sabahattin A Arı, Associate Professor","CONTACT","+905547139994","s.anil.ari.md@gmail.com",[37],{"facility":28,"status":18,"city":38,"state":39,"zip":40,"country":41,"countryCode":18,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Izmir","Menemen","35665","Turkey (Türkiye)",{"type":43,"coordinates":44},"Point",[45,46],27.13838,38.41273,{"lat":46,"lon":45},[49],{"name":32,"role":33,"phone":34,"phoneExt":18,"email":35},{"type":29,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Sabahattin Anıl Arı","Associate Professor","100622990","prophylactic-tranexamic-acid-in-low-risk-repeat-cesarean-delivery-a-randomized-controlled-trial-100622990",false,"NCT07390799","Prophylactic Tranexamic Acid in Low-Risk Repeat Cesarean Delivery: A Randomized Controlled Trial","Effect of Prophylactic Tranexamic Acid Administered After Fetal Delivery on Perioperative Blood Loss and Neonatal Outcomes in Low-Risk Repeat Cesarean Delivery: A Randomized Controlled Trial","Inclusion Criteria:\n\nWomen aged 18 to 45 years Singleton pregnancy Gestational age ≥37+0 weeks Scheduled second or third cesarean delivery Classified as low risk for postpartum hemorrhage Ability to provide written informed consent Planned cesarean delivery under regional or general anesthesia\n\nExclusion Criteria:\n\nPrimary cesarean delivery More than three previous cesarean deliveries Placenta previa, placenta accreta spectrum, or suspected abnormal placentation Multiple pregnancy Known coagulation disorders or use of anticoagulant therapy History of thromboembolic disease Severe anemia (hemoglobin \\\u003C10 g\u002FdL) Hypertensive disorders of pregnancy (including preeclampsia or eclampsia) Intrauterine fetal demise Emergency cesarean delivery Known hypersensitivity to tranexamic acid","FEMALE","18 Years","45 Years",{"count":64,"type":65},204,"ESTIMATED","INTERVENTIONAL",[68],"NA","Postpartum hemorrhage remains a leading cause of maternal morbidity following cesarean delivery. Tranexamic acid (TXA) has been shown to reduce blood loss when used for the treatment of postpartum hemorrhage; however, its routine prophylactic use during cesarean delivery, particularly in low-risk women, remains controversial. Large randomized trials have demonstrated limited benefit on major maternal outcomes, and data regarding clinically meaningful blood loss reduction and neonatal safety are still inconclusive.\n\nThis randomized controlled trial aims to evaluate the effect of prophylactic tranexamic acid administered after fetal delivery on perioperative blood loss in women undergoing low-risk repeat cesarean delivery. Secondary objectives include the assessment of neonatal outcomes to further evaluate the safety of routine TXA administration in this population.\n\nThe results of this study are expected to provide evidence to inform clinical decision-making regarding the routine use of tranexamic acid in low-risk repeat cesarean deliveries, balancing potential maternal benefits against neonatal safety considerations.",[71],"Cesarean Delivery",[22,73,74],"Repeat Cesarean Section","Perioperative Blood Loss","NOT_YET_RECRUITING","2026-01-29",{"date":78,"type":79},"2026-02-05","ACTUAL",{"date":81,"type":65},"2026-02-01",{"date":83,"type":65},"2026-09-30",{"name":5,"class":6},1]